ChiCTR2100053912
正在进行
/
/
/
2021-12-02
/
/
Dementia
Can whole-body vibration treatment optimize cognitive function in older adults who have sarcopenia and are at risk of dementia: A randomized controlled trial.
Can whole-body vibration treatment optimize cognitive function in older adults who have sarcopenia and are at risk of dementia: A randomized controlled trial.
The objective is to ascertain if vibration treatment optimizes cognitive function in older adults who have sarcopenia and are at risk of dementia.
随机平行对照
其它
In the randomization procedure, each participant will be assigned a special code generated by a computer. The statistician of the department will perform all the randomization and will not be involved in enrollment or outcome assessment.
Outcome assessor will be blinded. Participants are assumed to be not blinded; nevertheless, they will be reimnded not to tell the assessors about their group allocation. Research staff will not be involved in outcome assessment.
Health and Medical Research Fund
/
78
/
2021-12-17
2023-12-16
/
Community-living Chinese individuals aged 60 or older with sarcopenia but without clinical dementia will be recruited from local elderly centres equipped with our vibration platform, V-Health. All individuals will be screened at our research centre (the Orthopaedic Learning Centre) for the following: 1. presence of sarcopenia, defined according to the latest diagnostic criteria published by the Asian Working Group of Sarcopenia (AWGS): (1) hand-grip strength (male at < 28kg; female at < 18kg), (2) 6-metre gait speed test (< 1.0m/s), and (3) height-adjusted skeletal muscle mass measured by dual-energy X-ray absorptiometry (DXA, male at <7.0kg/m2 and female at < 5.4kg/m2), defined by appendicular skeletal muscle mass/height2 2. at risk of dementia, according to age- and education-matched cutoff of the Hong Kong Chinese version of Montreal Cognitive Assessment (HK-MoCA); 3. being able to stand independently without any aids; and 4. not receiving vibration treatment in the past 1 year.；
登录查看Exclusion criteria include non-Chinese ethnicity; living in care homes; having history of dementia, stroke, traumatic brain injury, epilepsy, or Parkinsons disease; taking drugs that affect cognition (benzodiazepines, anti-dementia medication, etc.); having history of severe mental illness (SMI), including bipolar affective disorder and schizophrenia, or substance abuse; already attending other cognitive intervention programs; significant impairments in communication; having any hormonal replacement therapy or drug treatment that could affect normal metabolism of musculoskeletal system; having any hypo- or hyperparathyroidism, renal, liver, or chronic inflammatory conditions known to affect muscle metabolism; having pacemaker or implant in situ; having difficulty in standing independently; and already having regular vibration treatment.；
登录查看Health and Medical Research Fund
/
药渡2025-01-19
亚泰制药2025-01-19
亚泰制药2025-01-19
约印创投2025-01-16
求实药社2025-01-16
Genhouse2025-01-16
IPHASE2025-01-16
动脉网2025-01-16
动脉网-最新2025-01-16
药明康德2025-01-16
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息
友情链接: 摩熵医药 摩熵医药企业版 摩熵化学MolAid 晓材Matmole 摩熵医学MedXYZ 载体质粒 觅健肿瘤互助 动脉网 药物百科
